(MedPage Today) — At the recent American Urological Association annual meeting, data on niraparib (Zejula) in treatment-naive, DNA damage repair (DDR)-deficient localized prostate cancer offered new insights — but also raised important questions…
Source link : https://www.medpagetoday.com/meetingcoverage/auavideopearls/115745
Author :
Publish date : 2025-05-23 16:23:00
Copyright for syndicated content belongs to the linked Source.
